Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

3 humongous healthcare stocks this week 4-18-14


Published on

This week's biggest health-care stocks

  • Be the first to comment

3 humongous healthcare stocks this week 4-18-14

  1. 1. 3 Humongous Health-Care Stocks This Week
  2. 2. Tax day came and went. Some fortunate investors in health-care stocks, though, are already potentially adding to their 2014 tax bills after racking up big gains over the past few days. Here are the week’s three most humongous health-care stocks.
  3. 3. Shares of the biopharmaceutical firm soared 55% this week. Akebia Therapeutics (Nasdaq:AKBA) Source: Yahoo! Finance
  4. 4. • 3 analysts gave positive ratings to the stock • Morgan Stanley reiterated an “overweight” rating with a $90 price target • Nomuria Securities recommended Akebia as a “buy” with a $39 price target • UBS AG announced a “buy” rating with a $28 price target • Each of these firms were involved with Akebia’s IPO earlier this year Why Akebia shares skyrocketed
  5. 5. Shares of the online health information provider climbed 19% higher for the week. WebMD (Nasdaq:WBMD) Source: Yahoo! Finance
  6. 6. • WebMD gave a positive Q1 update in advance of the April 30 earnings release • Revenue expected to be at the high end of the range previously given for Q1 and in top half of range given for full-year 2014 • Earnings for Q1 projected to be above previous estimates with full-year earnings also in top half of range provided earlier • Traffic in Q1 up 32% year-over-year in terms of unique users and up 26% for page views Why WebMD won big
  7. 7. Shares of the life sciences company jumped 16% this week. Repligen (Nasdaq:RGEN) Source: Yahoo! Finance
  8. 8. • Repligen joined the S&P SmallCap 600 Index • Replaced Hi-Tech Pharmacal, which is being acquired by drugmaker Akorn (Nasdaq:AKRX) • Repligen disappointed investors last quarter but expects solid revenue growth in 2014 of 10-15% Why Repligen roared
  9. 9. • WebMD claims an enviable status as the leading online source of health information and should continue to do well • Repligen also has a decent chance of solid gains in 2014, but my pick for most likely to stay humongous is Akebia Therapeutics • It’s certainly a speculative choice, but Akebia’s chronic kidney disease and anemia drug AKB- 6548 could prove to be a big winner for the small biopharmaceutical company • Morgan Stanley’s price target of $90 is probably too pie-in-the-sky, but good news from a phase 2b study later this year could turbocharge shares Best pick to stay humongous?
  10. 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!